Clinical Trial Update: Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CC-5013 in myelodysplastic syndrome assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• CC-5013 (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED